Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy

Neurology
Y HaratiM Kamin

Abstract

The objective of this study was to evaluate the efficacy and safety of tramadol in treating the pain of diabetic neuropathy. The pain of diabetic neuropathy is a major cause of morbidity among these patients and treatment, as with other small-fiber neuropathies, is often unsatisfactory. Tramadol is a centrally acting analgesic for use in treating moderate to moderately severe pain. This multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group study consisted of a washout/screening phase, during which all analgesics were discontinued, and a 42-day double-blind treatment phase. A total of 131 patients with painful diabetic neuropathy were treated with tramadol (n=65) or placebo (n=66) tramadol, which were administered as identical capsules in divided doses four times daily. The primary efficacy analysis compared the mean pain intensity scores in the tramadol and placebo groups obtained at day 42 of the study or at the time of discontinuation. Secondary efficacy assessments were the pain relief rating scores and a quality of life evaluation based on daily activities and sleep characteristics. Tramadol, at an average dosage of 210 mg/day, was significantly (p < 0.001) more effective than placebo for tre...Continue Reading

Citations

Jun 28, 2006·European Journal of Clinical Pharmacology·Ariel BergerGerry Oster
Jan 16, 2007·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Ariel BergerGerry Oster
Mar 20, 2003·Current Diabetes Reports·A J Boulton
Nov 13, 2003·Current Diabetes Reports·Singhan T M Krishnan, Gerry Rayman
Aug 31, 2004·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Rupa Shah, Barbara Carrig
Dec 1, 2005·Current Diabetes Reports·Roy Freeman
May 25, 2012·Current Diabetes Reports·Vincenza Spallone
Feb 14, 2006·Current Neurology and Neuroscience Reports·Betul M Gundogdu
May 2, 2003·Current Pain and Headache Reports·Richard BarbanoRobert H Dworkin
May 2, 2003·Current Pain and Headache Reports·Keri L Fakata, Arthur G Lipman
May 24, 2005·Current Pain and Headache Reports·Nathaniel Katz, Christine Benoit
Sep 10, 2008·Current Pain and Headache Reports·Douglas A DobeckiMark S Wallace
Feb 17, 2001·Current Treatment Options in Neurology·Anthony A. Amato, Richard J. Barohn
Apr 5, 2002·Current Treatment Options in Neurology·Gil I. Wolfe, Richard J. Barohn
Dec 22, 2004·Current Treatment Options in Neurology·J Robinson SingletonEva L Feldman
Jan 29, 2011·Current Treatment Options in Neurology·Lindsay Zilliox, James W Russell
Dec 14, 2005·Current Treatment Options in Neurology·Norah S Lincoff
Jun 1, 2013·Cell Biochemistry and Biophysics·Louis S Premkumar, Reddy M Pabbidi
Feb 5, 2004·Journal of the Neurological Sciences·Brian Brunelli, Kenneth C Gorson
May 9, 2003·Archives of Physical Medicine and Rehabilitation·Michael I WeintraubUNKNOWN Magnetic Research Group
May 21, 1999·Lancet·R H Dworkin
Mar 15, 2003·Clinical Therapeutics·Miroslav Backonja, Robert L Glanzman
Aug 26, 2000·Journal of Diabetes and Its Complications·Y HaratiM Kamin
Jun 13, 2003·Clinical Cornerstone·Aaron I Vinik
Aug 26, 2006·Nature Clinical Practice. Endocrinology & Metabolism·Aaron VinikCarolina M Casellini
Aug 9, 2001·Journal of Clinical Pharmacy and Therapeutics·R B Raffa
Feb 24, 2001·Journal of the American Geriatrics Society·F M Gloth
Feb 13, 2003·The American Journal of Nursing·Chris Pasero, Margo McCaffery
Apr 22, 2004·The Clinical Journal of Pain·Ahmad BeydounEnrique J Carrazana
May 21, 2003·American Journal of Therapeutics·Bill McCarbergSteven M Schmidt
Dec 1, 2002·Journal of Clinical Neuromuscular Disease·Gil I WolfeRichard J Barohn
Dec 1, 2003·Journal of Clinical Neuromuscular Disease·Thomas H Brannagan
Dec 13, 2005·The Clinical Journal of Pain·Mark P JensenPatricia Richards
Jun 15, 2006·The Clinical Journal of Pain·Michael C Rowbotham
Nov 3, 2004·The Neurologist·Clifton Gooch, David Podwall
Apr 1, 2009·The Clinical Journal of Pain·Cecilia Norrbrink, Thomas Lundeberg
May 5, 1999·Fundamental & Clinical Pharmacology·M BianchiA E Panerai
May 20, 2000·Acta Neurologica Scandinavica. Supplementum·T P Nash
May 20, 2000·Acta Neurologica Scandinavica. Supplementum·R N Harden
Jan 5, 2008·International Journal of Clinical Practice·R LikarR Sittl
Jan 24, 2011·Journal of Diabetes Investigation·Solomon Tesfaye
Aug 14, 2012·Pharmacological Reviews·Kevin L FarmerRick T Dobrowsky

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.